These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 19004236

  • 1. [Pentoxifylline old drug or new hope for nephrology?].
    Renke M, Rutkowski P, Tylicki L, Zietkiewicz M, Larczyński W, Rutkowski B.
    Przegl Lek; 2008; 65(7-8):358-61. PubMed ID: 19004236
    [Abstract] [Full Text] [Related]

  • 2. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M, Rutkowski P, Tylicki L, Zietkiewicz M, Larczyński W, Rutkowski B.
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [Abstract] [Full Text] [Related]

  • 3. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration.
    Navarro JF, Milena FJ, Mora C, León C, García J.
    Am J Nephrol; 2006; 26(6):562-70. PubMed ID: 17167242
    [Abstract] [Full Text] [Related]

  • 4. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.
    Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
    [Abstract] [Full Text] [Related]

  • 5. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
    Ryan MJ, Tuttle KR.
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383
    [Abstract] [Full Text] [Related]

  • 6. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
    Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB.
    J Nephrol; 2007 Sep; 20(4):410-6. PubMed ID: 17879206
    [Abstract] [Full Text] [Related]

  • 7. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
    Onuigbo MA.
    Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
    [Abstract] [Full Text] [Related]

  • 8. Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?
    Laverman GD, de Zeeuw D, Navis G.
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):205-13. PubMed ID: 12584664
    [Abstract] [Full Text] [Related]

  • 9. The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study.
    Renke M, Tylicki L, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydłowska W, Rutkowski B.
    Kidney Blood Press Res; 2008 Dec; 31(6):404-10. PubMed ID: 19092257
    [Abstract] [Full Text] [Related]

  • 10. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
    Bakris GL, Weir MR.
    Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
    [Abstract] [Full Text] [Related]

  • 11. Progression of chronic kidney disease: can it be prevented or arrested?
    Jaber BL, Madias NE.
    Am J Med; 2005 Dec; 118(12):1323-30. PubMed ID: 16378772
    [Abstract] [Full Text] [Related]

  • 12. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 13. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H, O'Keefe J.
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [Abstract] [Full Text] [Related]

  • 14. The hazards of dual renin-angiotensin blockade in chronic kidney disease.
    Ku E, Park J, Vidhun J, Campese V.
    Arch Intern Med; 2009 Jun 08; 169(11):1015-8. PubMed ID: 19506167
    [No Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme inhibitors in the therapy of renal diseases.
    Lefebvre HP, Toutain PL.
    J Vet Pharmacol Ther; 2004 Oct 08; 27(5):265-81. PubMed ID: 15500563
    [Abstract] [Full Text] [Related]

  • 16. Renin-angiotensin-aldosterone system and progression of renal disease.
    Rüster C, Wolf G.
    J Am Soc Nephrol; 2006 Nov 08; 17(11):2985-91. PubMed ID: 17035613
    [Abstract] [Full Text] [Related]

  • 17. Pentoxifylline: a potential therapy for chronic kidney disease.
    Lin SL, Chen YM, Chiang WC, Tsai TJ, Chen WY.
    Nephrology (Carlton); 2004 Aug 08; 9(4):198-204. PubMed ID: 15363050
    [Abstract] [Full Text] [Related]

  • 18. [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].
    Legrand D, Krzesinski JM, Scheen AJ.
    Rev Med Suisse; 2008 Aug 27; 4(168):1792-7. PubMed ID: 18814762
    [Abstract] [Full Text] [Related]

  • 19. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C, Schoemaker RG, van Gilst WH, Roks AJ.
    Clin Sci (Lond); 2009 Feb 27; 116(4):301-14. PubMed ID: 19138171
    [Abstract] [Full Text] [Related]

  • 20. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May 27; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.